Pregabalin

Tier C — Watch / trade

Pregabalin

Pfizer Inc.

Originator

2004

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：CACNA2D1

Brand：Regabatin, Lyrica

Indications (approved)：Fibromyalgia, Seizure, Postherpetic neuralgia, 神经痛, Partial-onset seizure, Diabetic neuropathy, Epilepsy, Anxiety disorder

Regional status

Approved

2004-12-30

Approved

2004-07-05

China

Approved

2010-05-07

Japan

Approved

2010-04-16

Factories producing this API2

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

2 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Pregabalin?

Approved indications include: Fibromyalgia, Seizure, Postherpetic neuralgia, 神经痛, Partial-onset seizure, Diabetic neuropathy, Epilepsy, Anxiety disorder.

When does the Pregabalin patent expire?

No public expiry year is available for Pregabalin yet; this page updates once verified.

How do I get a quote for Pregabalin intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27